Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Data Science Center, Jichi Medical University, Shimotsuke, Japan.
Geriatr Gerontol Int. 2023 Jul;23(7):500-505. doi: 10.1111/ggi.14600. Epub 2023 May 22.
Hypnotics might increase the risk of falls and fractures in older patients with neurocognitive disorders. Orexin receptor antagonists have recently been approved, but the relationship between the new drugs and fractures remains unclarified. This study aimed to evaluate the association between the type of hypnotic and in-hospital fractures in older patients with neurocognitive disorders using a nationwide inpatient database.
Using the Japanese Diagnosis Procedure Combination database, we collected information on inpatients aged ≥65 years with neurocognitive disorders between April 2014 and March 2021. We examined trends in the prescription patterns of benzodiazepine drugs, Z-drugs, orexin receptor antagonists and melatonin receptor agonists. We also carried out a 1:4 matched case-control analysis of in-hospital fractures. The odds ratio of each hypnotic drug was estimated using a generalized estimating equation with adjustment for walking ability, comorbidities, osteoporosis, dialysis, selective serotonin reuptake inhibitor use and anti-dementia drug use.
The prescription of benzodiazepine hypnotics decreased and that of orexin receptor antagonists increased. This case-control analysis included 6832 patients with fractures and 23 463 controls. Ultrashort-acting benzodiazepines, short-acting benzodiazepines and Z-drugs were associated with an increased risk of bone fracture (odds ratio [95% confidence interval] 1.38 [1.08-1.77], 1.38 [1.27-1.50], 1.49 [1.37-1.61], respectively). Orexin receptor antagonists were not associated with an increased risk of bone fracture (1.07 [0.95-1.19]).
In contrast to other types of hypnotics, orexin receptor antagonists were not associated with in-hospital fractures in older patients with neurocognitive disorders. Geriatr Gerontol Int 2023; 23: 500-505.
催眠药可能会增加伴有神经认知障碍的老年患者跌倒和骨折的风险。食欲素受体拮抗剂最近已获得批准,但新药物与骨折之间的关系仍不清楚。本研究旨在使用全国住院患者数据库评估伴有神经认知障碍的老年患者催眠药物类型与住院期间骨折之间的关系。
使用日本诊断程序组合数据库,我们收集了 2014 年 4 月至 2021 年 3 月期间年龄≥65 岁伴有神经认知障碍的住院患者的信息。我们检查了苯二氮䓬类药物、Z 类药物、食欲素受体拮抗剂和褪黑素受体激动剂的处方模式趋势。我们还对住院期间骨折进行了 1:4 匹配病例对照分析。使用广义估计方程,根据行走能力、合并症、骨质疏松症、透析、选择性 5-羟色胺再摄取抑制剂使用和抗痴呆药物使用情况调整后,估计每种催眠药物的比值比。
苯二氮䓬类催眠药的处方减少,食欲素受体拮抗剂的处方增加。这项病例对照分析包括 6832 名骨折患者和 23463 名对照。超短效苯二氮䓬类、短效苯二氮䓬类和 Z 类药物与骨折风险增加相关(比值比[95%置信区间] 1.38 [1.08-1.77]、1.38 [1.27-1.50]、1.49 [1.37-1.61])。食欲素受体拮抗剂与骨折风险增加无关(1.07 [0.95-1.19])。
与其他类型的催眠药相比,食欲素受体拮抗剂与伴有神经认知障碍的老年患者住院期间骨折无关。老年医学与老年病学国际 2023; 23: 500-505。